Please login to the form below
Tecentriq
This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
This included approvals for not only Keytruda, but also Roche’s Tecentriq (atezolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in a number of cancer types.
Latest news
-
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
tiragolumab. In January, the US Food and Drug Administration (FDA) issued a BTD for tiragolumab in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in the first-line setting for
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Roche’s immunotherapy Tecentriq has shown the first clinical improvement in post-surgery non-small cell lung cancer (NSCLC) although its benefit is limited to certain patients. ... In addition, Tecentriq increased DFS by a median of seven months
-
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
Initially, the FDA granted the Tecentriq/chemotherapy accelerated approval in this indication in March 2019 based on positive progression-free survival (PFS) results from the IMpassion130 study. ... However, it’s unclear what specific steps Roche will
-
Roche’s Tecentriq yields positive data in early stage NSCLC
Roche will continue to evaluate Tecentriq in the overall intent-to-treat population, which did not cross the threshold at the time of analysis. ... We’re excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly
-
NICE rejects Keytruda for advanced bladder cancer in final guidance
NICE said in its own statement that it now recommends Roche’s anti-PD-L1 drug Tecentriq (atezolizumab) for bladder cancer patients at this stage of the treatment pathway.
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
NICE rejects Keytruda for advanced bladder cancer in final guidance
More from news
Approximately 66 fully matching, plus 87 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).
-
The handover: Pfizer reshapes itself for a new era
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it
-
Cancer immunotherapy: What's on the horizon?
It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance
-
Europe vs the US: New drug product approvals
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
Immuno-oncology in 2019: the rapid evolution continues
The handover: Pfizer reshapes itself for a new era
Cancer immunotherapy: What's on the horizon?
Europe vs the US: New drug product approvals
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Blockchain for Tracking and Validating Medical Cannabis
- Improving Health Through Integrated & Personalized Patient Care
- Amanda Pritchard becomes NHS England’s first female chief executive
- GSK beats expectations thanks to strong vaccine sales in Q2
- AZ raises full-year guidance after completing Alexion acquisition in Q2
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Amanda Pritchard becomes NHS England’s first female chief executive
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
